Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 7/20 | 0.50 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.50 |
| ▸ | CSF1R | P07333 | 5/20 | 0.49 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CDK8 | P49336 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | IGF1R | P08069 | 1/20 | 0.43 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10073788 | 0.78 | KDR (0.59) | KDRPDGFRACSF1RTNNI3KFLT3 | |
| SCHEMBL10084379 | 0.72 | KDR (0.56) | KDRPDGFRACSF1RTNNI3KMEN1 | |
| SCHEMBL10083501 | 0.72 | CSF1R (0.64) | KDRCSF1RTNNI3KFLT3BRAF | |
| SCHEMBL13945907 | 0.71 | KDR (0.59) | KDRPDGFRACSF1RTNNI3KCDK8 | |
| SCHEMBL10084374 | 0.71 | CSF1R (0.54) | KDRPDGFRACSF1RTNNI3KFLT3 | |
| SCHEMBL11106394 | 0.69 | RAB9A (0.85) | MEN1KMT2ARAB9ANPC1KDM4E | |
| SCHEMBL12391532 | 0.69 | RAF1 (0.76) | KDRPDGFRACSF1RTNNI3KMEN1 | |
| SCHEMBL13945909 | 0.69 | KDR (0.50) | KDRPDGFRACSF1RTNNI3KFLT3 | |
| SCHEMBL21295574 | 0.68 | NPC1 (0.76) | MEN1KMT2ARAB9ANPC1KDM4E | |
| SCHEMBL10073785 | 0.68 | KDR (0.46) | KDRPDGFRACSF1RTNNI3KMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053192-A1 | Heterocyclic Substituted Acardite Derivate and Application Thereof | NANJING LUYESIKE PHARMACEUTICAL CO., LTD. (CN) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053192-A1 | Heterocyclic Substituted Acardite Derivate and Application Thereof | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, IDH1, CA7 | KDR 3633/4885PDGFRA 1115/4885CSF1R 2180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.